Tag: anti-CD19

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 27

Bispecific anti-CD20 and anti-CD19 CAR T Cell Therapy Shows Efficacy in B Cell M...

Nirav N. Shah, MD, an associate professor at the Medical College of Wisconsin, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor (CAR) T cells in a phase 1 dose escalation and expansion trial (NCT03019055) for relapsed B cell malignancies.

Read more
Targeted5

Unanswered Questions Remain in DLBCL With Use of CAR T-Cell Therapies

In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.

Read more
cell1

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off...

Human brain mural cells, essential for blood-brain barrier integrity, express CD19 and can then be potential off-tumor target for CD19-directed therapies, including CAR-T cells, suggesting a mechanism for associated neurotoxicity.
Read more
ImmunotherapyWebsite Images Featured 34

NextGen CARs: the race is on

In this issue of Blood, Tong et al present the preclinical and clinical development of an optimized, bivalent tandem CD20/CD19 chimeric antigen receptor (CAR) construct (see figure). Preclinically, they demonstrated dual-antigen specificity, enhanced immune synapse formation, and superior antitumor activity in vitro and in vivo in a murine xenograft model compared with alternative constructs generated from the same 2 single-chain variable fragment (scFv) regions derived from Leu-16 (anti-CD20) and FMC63 (anti-CD19) murine monoclonal antibodie.

Read more
blood a

Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large...

Cancer-associated venous thromboembolism (VTE) constitutes a major cause of morbidity and mortality in patients with hematologic malignancies.1 VTE can occur after chimeric antigen receptor (CAR) T-cell therapy, whereas coagulopathy in the form of low fibrinogen and bleeding can be complications of cytokine release syndrome (CRS).

Read more
blood cancer journal

Infection during the first year in patients treated with CD19 CAR T cells for di...

CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL).

Read more